Roche Holding AG (ROG.SW)
Exchange: Swiss Exchange
Currency: CHF
Price: 366.50 (Close)
Summary
52 Week range | 200d Moving Avg. | Beta |
288.55 – 374.22 | 357.70 | 0.31 |
Dividend | Dividend Yield | Ex-Dividend date |
9.30 | 2.54% | 2022-03-17 |
P/E Ratio | Latest EPS | DGR 3 years |
22.63 | 16.20 | 3.11% |
Overvalued
Low
Very low Volatility
High
Slow
Dividend Growth
Fast
Profile
Roche Holding AG diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases. The company provides diagnostic solutions, such as blood gas analysis; blood screening; cancer screening/monitoring; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring; coagulation routine and specialty testing; data management; diabetes monitoring; diabetes therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogeneous immuno assays; immunology; infectious diseases; intensive care testing; monitoring anti platelet therapy; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; physical fitness testing; platelet function testing; quality control service; real-time PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. Roche Holding AG has a strategic alliance with Wisconsin Diagnostic Laboratories; and a collaboration agreement with Five Prime Therapeutics, Inc. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Sector: | Industry: | |
Healthcare | Other | |
Total ESG Score
24 – 36 percentile
Environment
1 – 2 percentile
Social
14 – 2 percentile
Governance
10 – 2 percentile
Controversy level
2
MSCI ESG-Rating
n.a.
see MSCI ESG rating explained
Dividend Safety Metrics
Latest EPS | 16.20 | |
Annual Payout | 9.30 | |
Payout Ratio | 57.41% | |
Dividend growth | 33 Years | |
Dividend Score | 76 | |
Dividend Coverage Ratio | 1.74 | |
Altman-Z score | 0.00 |
Roche Holding AG (ROG.SW) Valuation
Roche Holding AG current dividend yield of 2.54% is -14% below its 5-year average. The 5-year average dividend yield is 2.96% (see red-line in chart). This indicates the stock looks overvalued today.
Roche Holding AG (ROG.SW) Performance
The chart below displays the total price return(%) of Roche Holding AG for different periods:
Roche Holding AG (ROG.SW) Total Return
The chart below displays the (CAGR) total return (%) including all dividends paid of Roche Holding AG for different periods:
Dividend Scorecard
Dividend Yield (TTM) | Annual Payout | Payout Ratio | Dividend growth |
2.54 | 9.30 | 57.41% | 33 Years |
Dividend Growth Summary
3 Year Growth Rate (CAGR) | 3.11% |
5 Year Growth Rate (CAGR) | 2.36% |
10 Year Growth Rate (CAGR) | 3.26% |
Dividend Growth Rates History
Year | Payout Amount | Annual Payout Growth (YoY) |
---|---|---|
2022 | 9.300 | 2.2% |
2021 | 9.100 | 1.1% |
2020 | 9.000 | 3.4% |
2019 | 8.700 | 4.8% |
2018 | 8.300 | 1.2% |
2017 | 8.200 | 1.2% |
2016 | 8.100 | 1.3% |
2015 | 8.000 | 2.6% |
2014 | 7.800 | 6.1% |
2013 | 7.350 | 8.1% |
2012 | 6.800 | 3.0% |
2011 | 6.600 | 10.0% |
2010 | 6.000 | 20.0% |
2009 | 5.000 | 8.7% |
2008 | 4.600 | 35.3% |
Roche Holding AG (ROG.SW) Dividend Payment History